Screener
Sutro Biopharma STRO CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Cash, cash equivalents and restricted cash at end of period | $74,540 | $107,087 |
| Supplemental disclosure of cash flow information: | ||
| Income tax paid (refunds received) | $(15) | $7 |
| Supplemental disclosure of non-cash investing and financing information: | ||
| Purchases of equipment included in accounts payable and accrued expense | — | $27 |
| Financing component associated with program fees | $911 | $1,176 |
| Issuance costs related to underwritten offering in accounts payable | $468 | — |
| Deferred offering cost included in accounts payable and accrued expenses | $435 | — |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's capex?
- Sutro Biopharma (STRO) reported capex of $0 in Q1 2026.
- How has Sutro Biopharma's capex changed year-over-year?
- Sutro Biopharma's capex decreased by 100.0% year-over-year, from $27K to $0.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Sutro Biopharma's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude